Spin-Off

A deep dive into Phaos Technology's 20-F filing reveals the stark contrast between public market capitalization and deep-tech commercialization hurdles.

The Chinese commercial EV maker is battling a collapsed stock price and dwindling cash, forcing a drastic ADS ratio change to maintain its US listing.

As Kawneer separates from Arconic under a $5.2 billion private equity buyout, a new leadership duo faces the monumental task of rewiring a 120-year-old giant.

As cyber threats and artificial intelligence redefine global risk, a 21-lawyer exodus from a legacy firm highlights a strategic shift in the legal industry.

Zhongchao's latest 1-for-2 reverse stock split highlights the grueling struggle of Chinese micro-cap healthcare VIEs battling Nasdaq delisting pressures.

KNOREX pitches its AscendX carve-out as a strategic AI pivot, but a forensic look at SEC filings reveals a desperate bid to save a depleted balance sheet.

Chanson International's return to profitability relies heavily on shadow lending and extreme capital dilution, masking deep operational retail losses.

Newly independent Ennature Biopharma is betting on validated science for its botanicals, aiming to lead the booming women's health market with transparency.

Formerly biotech firm BiomX, Tessera has executed a high-stakes pivot to defense, betting its future on protecting the world's critical infrastructure.

A 25-for-1 reverse split saves Intercont from Nasdaq delisting, but the real test is if its 'seaborne pulping' vision is a viable future or a fantasy.

Facing Nasdaq delisting, Israeli tech firm HUB Cyber Security executes a 1-for-25 reverse split. Is it a lifeline or a sign of deeper trouble?

A veteran team from Blue Sea Capital launches Reefline, a new PE firm doubling down on a proven playbook for aerospace, defense, and industrial growth.

Robinhood takes an equity stake in Crypto.com's $5B spinoff, OG.com, in a landmark deal to dominate the booming, regulated prediction markets space.

Facing delisting, BioRestorative executes another reverse split. We dive into whether this financial maneuver can sustain it or just delays the inevitable.

Capstone retired 75% of its dilutive convertible notes, a major milestone. But with a low stock price and reliance on an equity line, is this a true pivot?

Interpace Biosciences is engineering its stock for a Nasdaq uplist, but is this financial maneuver a path to sustained growth or a classic warning sign?

From explorer to producer, PDI Gold's name change and share consolidation signal a bold new chapter. But can it navigate financial hurdles and regional risks?

MDB Capital celebrates a string of successful IPOs but reports a staggering $16.1M loss, putting its unique 'public venture' model under intense scrutiny.

MSG Sports posts record profits fueled by a Knicks NBA title, but the real story is the strategic gamble to split its empire, creating long-term risks.

Haoxi Health announces a second reverse split in three months, a move to save its Nasdaq listing that investors see as a red flag, despite its strategic AI push.